Terminated PHASE2 INTERVENTIONAL NCT00230334

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

Sponsor: Novartis

Conditions Eosinophilia Hypereosinophilic Syndrome

Interventions Gleevec

Updated 6 times since 2017 Last updated: May 5, 2021 Started: Jun 12, 2003 Primary completion: Dec 29, 2006 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

terminated by PI due to insufficient accrual

Other terminated trials from Novartis

See all terminations from Novartis

This PHASE2 trial investigates Eosinophilia and Hypereosinophilic Syndrome and is currently terminated or withdrawn. Novartis leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jun 2021 — Jul 2024 [monthly]

Terminated PHASE2

Status: Withdrawn → Terminated
Jan 2021 — Jun 2021 [monthly]

Withdrawn PHASE2
Jun 2018 — Jan 2021 [monthly]

Withdrawn PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Withdrawn PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Steven E. Coutre

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States